source
- FDA delays AstraZeneca breast cancer drug camizestrant PDUFA dateThe U.S. Food and Drug Administration has extended the PDUFA target date for AstraZeneca’s breast cancer candidate camizestrant, pushing the review timeline back by a few days. No new deadline was…
- Mentari Therapeutics to go public via reverse merger with InMed, raising $290 million for migraine antibody programsMentari Therapeutics, a spinout of Paragon, announced a reverse merger with InMed Pharmaceuticals that will take the company public under the Mentari name. The deal has received board approval fro…